EX-99.1 2 d155918dex991.htm EX-99.1 EX-99.1

Exhibit 99.1

 

LOGO

HEXO Corp. Condensed Interim Consolidated Financial Statements For the three and nine months ended April 30, 2021 and 2020


Table of Contents

 

Condensed Interim Consolidated Statements of Financial Position      1  
Condensed Interim Consolidated Statements of Net Loss and Comprehensive Loss      2  
Condensed Interim Consolidated Statements of Changes in Shareholders’ Equity      3  
Condensed Interim Consolidated Statements of Cash Flows      4  
Notes to the Condensed Interim Consolidated Financial Statements:   
1. Description of Business      5  
2. Basis of Preparation      5  
3. New Accounting Policies and Pronouncements      5  
4. Restricted Funds      6  
5. Commodity Taxes Recoverable and Other Receivables      6  
6. Inventory      6  
7. Biological Assets      7  
8. Investments in Associates & Joint Ventures      7  
9. Long-term Investments      8  
10. Property, Plant and Equipment      8  
11. Intangible Assets      9  
12. Convertible Debenture Receivable      9  
13. Warrant Liabilities      9  
14. Convertible Debentures      10  
15. Lease Liabilities      10  
16. Term Loan      11  
17. Share Capital      11  
18. Common Share Purchase Warrants      12  
19. Share-based Compensation      13  
20. Net Loss per Share      15  
21. Financial Instruments      15  
22. Operating Expenses by Nature      17  
23. Other Income and Losses      17  
24. Related Party Disclosure      18  
25. Capital Management      18  
26. Commitments and Contingencies      19  
27. Fair Value of Financial Instruments      20  
28. Non-Controlling Interest      20  
29. Revenue from Sale of Goods      21  
30. Segmented Information      21  
31. Operating Cash Flow      21  
32. Comparative Information      22  
33. Income Taxes      22  
34. Subsequent Events      22  


Condensed Interim Consolidated Statements of Financial Position

(Unaudited, expressed in thousands of Canadian Dollars)

 

As at

   Note      April 30, 2021     July 31, 2020  

Assets

       

Current assets

       

Cash and cash equivalents

      $ 81,038     $ 184,173  

Restricted funds

     4        32,551       8,261  

Trade receivables

        19,049       19,426  

Commodity taxes recoverable and other receivables

     5        10,202       16,733  

Prepaid expenses

        4,386       4,606  

Inventory

     6        95,223       64,933  

Biological assets

     7        9,222       7,571  
     

 

 

   

 

 

 
        251,671       305,703  
     

 

 

   

 

 

 

Non-current assets

       

Property, plant and equipment

     10        280,183       285,366  

Intangible assets

     11        16,412       16,008  

Convertible debenture receivable

     12        20,246       —    

Investment in associate and joint ventures

     8        73,379       76,306  

Lease receivable

        3,795       3,865  

License and prepaid royalty

        —         1,020  

Long-term investments

     9        4,402       3,209  

Prepaid expenses

        3,101       1,392  
     

 

 

   

 

 

 
        653,189       692,869  
     

 

 

   

 

 

 

Liabilities

       

Current liabilities

       

Accounts payable and accrued liabilities

        42,968       32,451  

Excise taxes payable

        4,315       7,121  

Warrant liabilities

     13        13,037       3,450  

Lease liability

     15        4,659       4,772  

Term loan

     16        —         29,930  

Onerous contract

     26        4,763       4,763  
     

 

 

   

 

 

 
        69,742       82,487  
     

 

 

   

 

 

 

Non-current liabilities

       

Lease liability

     15        22,566       24,344  

Convertible debentures

     14        31,951       28,969  

Other long-term liabilities

        1,805       393  
     

 

 

   

 

 

 
        126,064       136,193  
     

 

 

   

 

 

 

Shareholders’ equity

       

Share capital

     17        1,031,525       1,023,788  

Share-based payment reserve

     19        66,381       65,746  

Warrant reserve

     18        93,429       95,617  

Contributed surplus

        37,386       27,377  

Accumulated deficit

        (704,978     (659,231

Accumulated other comprehensive income

        3       —    

Non-controlling interest

     28        3,379       3,379  
     

 

 

   

 

 

 
        527,125       556,676  
     

 

 

   

 

 

 
        653,189       692,869  
     

 

 

   

 

 

 
Commitments and contingencies (Note 26)         
Subsequent events (Note 34)         

Approved by the Board of Directors

/s/ Jason Ewart, Director

/s/ Michael Munzar, Director

 

1


Condensed Interim Consolidated Statements of Net Loss and Comprehensive Loss

(Unaudited, expressed in thousands of Canadian Dollars, except per share data)

 

            For the three months ended     For the nine months ended  
     Note      April 30,
2021
    April 30,
2020
    April 30,
2021
    April 30,
2020
 

Revenue from sale of goods

     29        33,082       30,895       120,059       74,009  

Excise taxes

        (10,482     (8,817     (35,219     (20,516
     

 

 

   

 

 

   

 

 

   

 

 

 

Net revenue from sale of goods

        22,600       22,078       84,840       53,493  

Ancillary revenue

        60       54       168       145  
     

 

 

   

 

 

   

 

 

   

 

 

 

Net revenue

        22,660       22,132       85,008       53,638  

Cost of goods sold

     6,22        18,281       13,530       57,391       76,914  
     

 

 

   

 

 

   

 

 

   

 

 

 

Gross profit/(loss) before fair value adjustments

        4,379       8,602       27,617       (23,276

Realized fair value amounts on inventory sold

     6        6,426       9,251       17,619       21,362  

Unrealized gain on changes in fair value of biological assets

     7        (10,863     (6,379     (35,616     (21,378
     

 

 

   

 

 

   

 

 

   

 

 

 

Gross profit/(loss)

        8,816       5,730       45,614       (23,260

Operating expenses

           

Selling, general and administrative

     22        14,822       11,238       39,039       40,833  

Marketing and promotion

        2,452       2,131       6,682       9,621  

Share-based compensation

     22        2,715       6,171       10,904       22,237  

Research and development

        730       1,017       2,901       3,962  

Depreciation of property, plant and equipment

     10        1,612       1,566       4,369       4,890  

Amortization of intangible assets

     11        371       341       1,043       3,690  

Restructuring costs

        336       865       1,721       4,846  

Impairment of property, plant and equipment

     10        16       220       881       33,004  

Impairment of intangible assets

     11        —         —         —         106,189  

Impairment of goodwill

        —         —         —         111,877  

Recognition of onerous contract

        —         —         —         3,000  

Disposal of long-lived assets

        —         —         1,294       —    

Loss/(gain) on disposal of property, plant and equipment

        (19     3,237       45       3,734  

Acquisition and transaction costs

        1,871       —         2,307       —    
     

 

 

   

 

 

   

 

 

   

 

 

 
        24,906       26,786       71,186       347,883  
     

 

 

   

 

 

   

 

 

   

 

 

 

Loss from operations

        (16,090     (21,056     (25,572     (371,143
     

 

 

   

 

 

   

 

 

   

 

 

 

Finance income (expense), net

     23        (2,947     (2,926     (7,311     (6,073

Non-operating income (expense), net

     23        (1,674     4,463       (12,864     (6,717
     

 

 

   

 

 

   

 

 

   

 

 

 

Loss and comprehensive loss attributable to shareholders before tax

        (20,711     (19,519     (45,747     (383,933
     

 

 

   

 

 

   

 

 

   

 

 

 

Income tax recovery

        —         —         —         6,023  
     

 

 

   

 

 

   

 

 

   

 

 

 

Other comprehensive income

           

Foreign currency translation

        3       —         3       —    
     

 

 

   

 

 

   

 

 

   

 

 

 

Net loss and comprehensive loss

        (20,708     (19,519     (45,744     (377,910
     

 

 

   

 

 

   

 

 

   

 

 

 

Comprehensive loss attributable to:

           
     

 

 

   

 

 

   

 

 

   

 

 

 

Shareholders of HEXO Corp.

        (20,708     (19,519     (45,744     (377,910
     

 

 

   

 

 

   

 

 

   

 

 

 

Non-controlling interest

        —         —         —         —    
     

 

 

   

 

 

   

 

 

   

 

 

 
        (20,708     (19,519     (45,744     (377,910
     

 

 

   

 

 

   

 

 

   

 

 

 

Net loss per share, basic and diluted

        (0.17     (0.26     (0.38     (5.56
     

 

 

   

 

 

   

 

 

   

 

 

 

Weighted average number of outstanding shares

           

Basic and diluted

     20        122,397,731       73,852,844       121,749,456       67,936,412  
     

 

 

   

 

 

   

 

 

   

 

 

 

 

2


Condensed Interim Consolidated Statements of Changes in Shareholders’ Equity

(Unaudited, expressed in thousands of Canadian Dollars, except per share data)

 

For the nine months ended

   Note      Number of
common shares
     Share
capital
    Share-based
payment
reserve
    Warrant
reserve
    Contributed
surplus
    Non-controlling
interest
     Other
comprehensive
Income
     Accumulated
deficit
    Shareholders’
equity
 

Balance at July 31, 2019

        64,245,438        799,706       40,315       60,433       —         1,000        —          (112,742     788,712  

April 2020 underwritten offering

        14,950,000        25,864       —         20,182       —         —          —          —         46,046  

$70m private placement unsecured convertible debentures

        —          —         —         —         23,902       —          —          —         23,902  

USD$25m registered offering

        3,742,516        26,782       —         —         —         —          —          —         26,782  

USD$20m registered offering

        2,994,012        22,323       —         —         —         —          —          —         22,323  

Issuance fees

        —          (5,570     —         —         (27     —          —          —         (5,597

Expiry of warrants

        —          —         —         (7,141     7,141       —          —          —         —    

Exercise of warrants

        17,856        177       —         —         —         —          —          —         177  

Exercise of stock options

     19        29,133        223       (88     —         —         —          —          —         135  

Expiry of stock options

        —          —         (312     —         312       —          —          —         —    

Equity-settled share-based payments

     19,22        —          —         27,326       —         —         —          —          —         27,326  

Net loss and comprehensive loss

        —          —         —         —         —         —          —          (377,910     (377,910
     

 

 

    

 

 

   

 

 

   

 

 

   

 

 

   

 

 

    

 

 

    

 

 

   

 

 

 

Balance at April 30, 2020

        85,978,955        869,505       67,241       73,474       31,328       1,000        —          (490,652     551,896  
     

 

 

    

 

 

   

 

 

   

 

 

   

 

 

   

 

 

    

 

 

    

 

 

   

 

 

 

Balance at July 31, 2020

        120,616,441        1,023,788       65,746       95,617       27,377       3,379        —          (659,231     556,676  

June 2020 at the market offering

     17        244,875        —         —         —         —         —          —          —         —    

Issuance fees

        —          (192     —         —         —         —          —          —         (192

Exercise of stock options

     19        82,083        499       (195     —         —         —          —          —         304  

Expiry of stock options

        —          —         (9,507     —         9,507       —          —          —         —    

Exercise of warrants

        1,522,139        7,430       —         (2,188     131       —          —          —         5,373  

Expiry of warrants

        —          —         —         —         —         —          —          —         —    

Equity-settled share-based payments

     19,22        —          —         10,337       —         —         —          —          —         10,337  

Other comprehensive income

        —          —         —         —         —         —          3        —         3  

Non-controlling interest

     28        —          —         —         —         371       —          —          —         371  

Net loss and comprehensive loss

        —          —         —         —         —         —          —          (45,747     (45,747
     

 

 

    

 

 

   

 

 

   

 

 

   

 

 

   

 

 

    

 

 

    

 

 

   

 

 

 

Balance at April 30, 2021

        122,465,538        1,031,525       66,381       93,429       37,386       3,379        3        (704,978     527,125  
     

 

 

    

 

 

   

 

 

   

 

 

   

 

 

   

 

 

    

 

 

    

 

 

   

 

 

 

 

3


Condensed Interim Consolidated Statements of Cash Flows

(Unaudited, expressed in thousands of Canadian Dollars)

 

For the nine months ended

   Note      April 30, 2021     April 30, 2020  

Operating activities

       

Total net loss

      $ (45,744   $ (377,910

Items not affecting cash

     31        24,102       343,929  

Changes in non-cash operating working capital items

     31        4,804       (59,650
     

 

 

   

 

 

 

Cash used in operating activities

        (16,838     (93,631
     

 

 

   

 

 

 

Financing activities

       

Issuance of common shares

        883       104,748  

Issuance fees

        (192     (5,773

Proceeds from the exercise of stock options

     19        304       135  

Proceeds from the exercise of warrants

     18        5,373       71  

Payments on term loan

     16        (30,625     (2,625

Lease payments

     15        (3,476     (3,196

Issuance of unsecured convertible debentures

     14        —         70,000  

Interest paid on unsecured convertible debentures

     14        (2,409     (1,804
     

 

 

   

 

 

 

Cash used financing activities

        (30,142     161,556  
     

 

 

   

 

 

 

Investing activities

       

Settlement of short-term investments

        —         24,726  

Proceeds from sale of investments

        —         8,258  

Restricted cash

     4        (24,290     4,967  

Issuance of convertible debenture receivable

     12        (19,500     —    

Proceeds from sale of property, plant and equipment

        102       716  

Acquisition of property, plant and equipment

        (8,045     (95,998

Purchase of intangible assets

        (1,447     (617

Investment in associate and joint ventures

     8        (2,975     (29,220
     

 

 

   

 

 

 

Cash used in investing activities

        (56,155     (87,168
     

 

 

   

 

 

 

Cash used

        (103,135     (19,243

Cash and cash equivalents, beginning of period

        184,173       113,568  
     

 

 

   

 

 

 

Cash and cash equivalents, end of period

        81,038       94,325  
     

 

 

   

 

 

 

 

Supplemental cashflow information in Note 31.

The accompanying notes are an integral part of these consolidated financial statements.

 

4


Notes to the Consolidated Financial Statements

For the three and nine months ended April 30, 2021 and 2020

(Unaudited, expressed in thousands of Canadian Dollars, except share amounts or where otherwise stated)

1. Description of Business

HEXO Corp. (the “Company”), is a publicly traded corporation, incorporated in Ontario. HEXO is licensed to produce and sell cannabis and cannabis products under the Cannabis Act. Its head office is located at 3000 Solandt Road Ottawa, Canada. The Company’s common shares are listed on the Toronto Stock Exchange (“TSX”) and the New York Stock Exchange (“NYSE”), both under the trading symbol “HEXO”.

COVID-19

In March 2020, the World Health Organization declared the outbreak of COVID-19 a global pandemic. In response to the outbreak, governmental authorities in Canada and internationally have introduced various recommendations and measures to try to limit the pandemic, including travel restrictions, border closures, non- essential business closures, quarantines, self-isolations, shelters-in-place and social distancing. These measures are continuously monitored and modified by the applicable governmental authorities in Canada and remained in effect as at April 30, 2021. The production and sale of cannabis in Canada was deemed an essential service throughout the three and nine months ended April 30, 2021.

The Company regularly monitors the impact of the ongoing pandemic on all aspects of its business and operations and as of April 30, 2021, we have not observed any material changes.

2. Basis of Preparation

Statement of Compliance

These condensed interim consolidated financial statements (“interim consolidated financial statements”) have been prepared in accordance with International Accounting Standard 34, Interim Financial Reporting (“IAS 34”), using accounting policies consistent with International Financial Reporting Standards as issued by the International Accounting Standards Board and IFRS Interpretations Committee (“IFRS”). These interim consolidated financial statements do not contain all the disclosures required in annual consolidated financial statements and should be read in conjunction with the amended and restated annual consolidated financial statements of the Company for the year ended July 31, 2020, prepared in accordance with IFRS.

The interim consolidated financial statements have been prepared using accounting policies consistent with those described in the annual consolidated financial statements for the year ended July 31, 2020.

These interim consolidated financial statements were approved and authorized for issue by the Board of Directors on June 14, 2021.

3. New Accounting Policies and Pronouncements

New Accounting Policy

CAPTIVE INSURANCE

Insurance coverage for the Company’s directors and officers has been secured through a Captive Cell program (“the Captive Program”). The Captive Program was effected by entering into a participation agreement with a registered insurer for the purposes of holding and managing the Company’s coverage funds through a separate cell account (the “Cell Captive”). The Company applies IFRS 10 Consolidated Financial Statements in its assessment of control as it relates to the Cell Captive. The Company’s accounting policy is to consolidate the Cell Captive. Currently the Captive Program funds are held as cash in the Cell Captive with the possibility of reinvestment into short-term investments and/or marketable securities in the future. As the funds cannot be transferred to other parts of the group without providing 6 month notice, the funds are disclosed as Restricted cash. The Company recognizes gains and losses from, interest, foreign exchange activity and/or fair market value adjustments through the Statement of Loss and Comprehensive Loss.

New Accounting Procurement Not Yet Effective

AMENDMENTS TO IAS 37: ONEROUS CONTRACTS AND THE COST OF FULFILLING A CONTRACT

The amendment specifies that the ‘cost of fulfilling’ a contract comprises the ‘costs that relate directly to the contract’. Costs that relate directly to a contract consist of both the incremental costs of fulfilling that contract or an allocation of other costs that relate directly to fulfilling contracts. The amendment is effective for annual periods beginning on or after January 1, 2022 with early application permitted. The Company is currently evaluating the potential impact of these amendments on the Company’s consolidated financial statements.

 

5


4. Restricted Funds

 

     April 30, 2021      July 31, 2020  
     $      $  
Debt service reserve account – term loan (Note 16)      —          8,191  

Letters of credit, collateral and guarantees for purchases

     2,552        70  

Captive insurance

     29,999        —    
  

 

 

    

 

 

 

Total

     32,551        8,261  
  

 

 

    

 

 

 

5. Commodity Taxes Recoverable and Other Receivables

 

     April 30, 2021      July 31, 2020  

Commodity taxes recoverable

   $ 3,167      $ 12,821  

Lease receivable – current1

     630        630  

Other receivables

     6,405        3,282  
  

 

 

    

 

 

 

Total

   $ 10,202      $ 16,733  
  

 

 

    

 

 

 

 

1 

A related party capital lease receivable related to Truss Limited Partnership (Note 24).

6. Inventory

 

     As at April 30, 2021  
     Capitalized
cost
     Biological asset fair
value adjustment
     Total  

Dried cannabis

   $ 46,707      $ 28,309      $ 75,016  

Purchased dried cannabis

     1,666        —          1,666  

Extracts

     10,688        96        10,784  

Purchased extracts

     856        —          856  

Hemp derived distillate

     49        —          49  

Packaging and supplies

     6,852        —          6,852  
  

 

 

    

 

 

    

 

 

 
   $ 66,818      $ 28,405      $ 95,223  
  

 

 

    

 

 

    

 

 

 

 

     As at July 31, 2020  
     Capitalized
cost
     Biological asset fair
value adjustment
     Total  

Dried cannabis

   $ 29,702      $ 16,981      $ 46,683  

Purchased dried cannabis

     1,956        —          1,956  

Extracts

     4,828        385        5,213  

Purchased extracts

     5,977        —          5,977  

Hemp derived distillate

     566        —          566  

Packaging and supplies

     4,538        —          4,538  
  

 

 

    

 

 

    

 

 

 
   $ 47,567      $ 17,366      $ 64,933  
  

 

 

    

 

 

    

 

 

 

Capitalized costs relating to inventory expensed and included in Cost of goods sold were $17,654 and $57,934 for the three and nine months ended April 30, 2021, respectively (April 30, 2020 – $13,349 and $34,765). The unrealized fair value gain on biological asset fair value adjustments on the consolidated statement of loss for the three and nine months ended April 30, 2021 were $10,863 and $35,616, respectively (April 30, 2020 – $6,379 and $21,378). The realized fair value amounts on inventory sold on the consolidated statement of loss was $6,426 and $17,619 for the three and nine months ended April 30, 2021, respectively (April 30, 2020 – $9,251 and $21,362). During the three and nine months ended April 30, 2021, the Company reversed certain prior period inventory write downs of $nil and $1,543, respectively (April 30, 2020 – $nil and $nil) recorded in costs of sales on the consolidated statement of loss and $nil and $688 (April 30, 2020 – $nil and $nil) of fair value recorded in fair value amounts on inventory sold.

Total share-based compensation capitalized to inventory in the nine months ended April 30, 2021 was $1,283 (April 30, 2020 –$5,089). Total depreciation capitalized to inventory in the nine months ended April 30, 2021 was $10,850 (April 30, 2020 – $8,221).

 

6


7. Biological Assets

The Company’s biological assets consist of cannabis plants throughout the growth cycle, from mother plants to plants in propagation, vegetative and flowering stages. The changes in the carrying value of biological assets are as follows:

 

     For the nine
months ended
April 30, 2021
     For the year ended
July 31, 2020
 
     $      $  

Balance, beginning of year

     7,571        7,371  

Production costs capitalized

     23,819        38,638  

Net increase in fair value due to biological transformation and estimates

     35,616        29,356  

Transferred to inventory upon harvest

     (57,784      (67,131

Disposal of biological assets

     —          (663
  

 

 

    

 

 

 

Balance, end of period

     9,222        7,571  
  

 

 

    

 

 

 

The valuation of biological assets is based on an income approach (Level 3) in which the fair value at the point of harvesting is estimated based on selling prices less the costs to sell. For in process biological assets, the fair value at the point of harvest is adjusted based on the stage of growth at period-end.

The significant estimates used in determining the fair value of cannabis plants are as follows:

 

   

yield per plant;

 

   

stage of growth percentage estimated as costs incurred as a percentage of total cost as applied to the estimated total fair value per gram (less fulfilment costs) to arrive at an in-process fair value for estimated biological assets, which have not yet been harvested;

 

   

percentage of costs incurred for each stage of plant growth.

 

   

fair value selling price per gram less cost to complete and cost to sell.

 

   

destruction/wastage of plants during the harvesting and processing process.

Management’s identified significant unobservable inputs, their range of values and sensitivity analysis are presented in the tables below.

 

     Input values   An increase or decrease of 5% applied to
the unobservable input would result in a change
to the fair value of approximately

Unobservable inputs

  April 30, 2021   July 31, 2020   April 30, 2021   July 31, 2020

Weighted average selling price

Derived from actual retail prices on a per product basis using the expected Flower and Trim yields per plant.

  $2.81 per dried

gram

  $3.23 per dried

gram

  $746   $550

Yield per plant

Derived from historical harvest cycle results on a per strain basis.

  80 – 113 grams

per plant

  46 – 135 grams

per plant

  $746   $376

Stage of growth

Derived from the estimates of stage of completion within the harvest cycle.

  Average of 50%

completion

  Average of 43%

completion

  $460   $376

Waste

Derived from the estimates of planned removal and naturally occurring waste within the cultivation and production cycle.

  0%–21%

dependent upon
the stage within
the harvest cycle

  0%–21%

dependent upon
the stage within
the harvest cycle

  No material variance   No material variance

8. Investments in Associates & Joint Ventures

 

     For the nine months ended April 30, 2021     For the year ended July 31, 2020  
     Truss LP     Other     Total     Truss LP     Other     Total  
     $     $     $     $     $     $  

Opening Balance

     74,966       1,340       76,306       51,786       1,063       52,849  

Cash contributed to investment

     2,975       —         2,975       29,155       1,231       30,386  

Capitalized transaction costs

     —         —         —         —         109       109  

Share of net (loss)

     (5,638     (264     (5,902     (5,975     (356     (6,331

Impairment

     —         —         —         —         (707     (707
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Ending Balance

     72,303       1,076       73,379       74,966       1,340       76,306  
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

 

7


Truss LP

The Truss Limited Partnership (“Truss LP”) is a joint arrangement between the Company and Molson Coors Canada (the “Partner”) and is a standalone entity, incorporated in Canada, with its own board of directors and an independent management team. The Partner holds 57,500 common shares representing 57.5% controlling interest in Truss with the Company holding 42,500 common shares and representing the remaining 42.5%. Truss is a private limited partnership and its principal operating activities consist of pursuing opportunities to develop non-alcoholic, cannabis-infused beverages (Note 24). During the nine months ended April 30, 2021 the Company contributed $2,975 of additional capital to Truss as required under the shareholders agreement.

9. Long-term Investments

 

     Units      Fair value
July 31,
2020
     Divestiture     Change in
fair value
     Fair value
April 30,
2021
 
            $      $     $      $  

Level 1 Investments

             

Fire and Flower common shares

     1,319,377        1,292        —         171        1,463  

Inner Spirit common shares

     8,994,500        1,260        —         1,033        2,293  

Other long-term investments

     n/a        517        (11     —          506  

Level 3 Investments

             

Segra International Corp.

     400,000        140        —         —          140  
  

 

 

    

 

 

    

 

 

   

 

 

    

 

 

 

Total

        3,209        (11     1,204        4,402  
  

 

 

    

 

 

    

 

 

   

 

 

    

 

 

 

10. Property, Plant and Equipment

 

Cost

  Land     Buildings     Leasehold
improvements
    Cultivation
and production
equipment
    Furniture,
computers,
vehicles and
equipment
    Construction
in progress
    Right-of-Use
assets
    Total  
    $     $     $     $     $     $     $     $  

At July 31, 2019

    5,339       150,834       627       42,029       10,368       57,550       —         266,747  

Additions

    —         24,432       1,395       14,969       9,404       66,246       24,405       140,851  

Disposals

    (3,683     (18,260     —         (13,402     (909     (5,428     —         (41,682

Transfers

    —         7,943       22,417       (10,135     8       (20,233     —         —    
 

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

At July 31, 2020

    1,656       164,949       24,439       33,461       18,871       98,135       24,405       365,916  
 

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Additions

    —         873       63       2,014       234       7,978       —         11,162  

Disposals

    —         (5     —         (51     —         —         (1,055     (1,111

Transfers

    —         3,929       15,685       764       888       (21,089     —         177  
 

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

At April 30, 2021

    1,656       169,746       40,187       36,188       19,993       85,024       23,350       376,144  
 

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Accumulated depreciation and impairments

 

           

At July 31, 2019

    —         4,392       130       2,216       1,216       —         —         7,954  

Depreciation

    —         7,395       879       3,702       3,562       —         2,522       18,060  

Transfers

    —         —         —         271       (271     —         —         —    

Disposals

    —         (17,081     —         (7,435     (366     —         —         (24,882

Impairments

    307       19,006       —         9,937       —         48,990       1,178       79,418  
 

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

At July 31, 2020

    307       13,712       1,009       8,691       4,141       48,990       3,700       80,550  
 

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Depreciation

    —         5,529       1,525       3,481       2,865       —         1,819       15,219  

Transfers

    —         454       (16     27       (190     —         —         275  

Disposals

    —         —         —         —         —         —         (964     (964

Impairments

    —         —         85       (20     61       (6     761       881  
 

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

At April 30, 2021

    307       19,695       2,603       12,179       6,877       48,984       5,316       95,961  
 

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Net book value

 

           

At July 31, 2019

    5,339       146,442       497       39,813       9,152       57,550       —         258,793  

At July 31, 2020

    1,349       151,237       23,430       24,770       14,730       49,145       20,705       285,366  
 

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

At April 30, 2021

    1,349       150,051       37,584       24,009       13,116       36,040       18,034       280,183  
 

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

In the nine months ended April 30, 2021, the Company capitalized $10,850 (July 31, 2020 — $11,988) of depreciation to inventory. During the three and nine months ended April 30, 2021, depreciation expensed to the consolidated statement of loss and comprehensive loss was $1,612 and $4,369 (April 30, 2020 — $1,566 and $4,890).

Capitalized borrowing costs to buildings in the nine months ended April 30, 2021 were $1,269 (July 31, 2020 — $2,385) at an average interest rate of 5.6% (July 31, 2020 — 7.22%).

 

8


11. Intangible Assets

 

Cost

   Cultivating and
processing license
     Brand      Software     Domain
names
     Patents     Total  
     $      $      $     $      $     $  

At July 31, 2019

     116,433        8,440        3,558       585        1,231       130,247  

Additions

     —          —          702       —          875       1,577  

Disposals

     —          —          (550     —          (173     (723
  

 

 

    

 

 

    

 

 

   

 

 

    

 

 

   

 

 

 

At July 31, 2020

     116,433        8,440        3,710       585        1,933       131,101  

Additions

     —          —          896       —          551       1,447  

Disposals

     —          —          (872     —          —         (872
  

 

 

    

 

 

    

 

 

   

 

 

    

 

 

   

 

 

 

At April 30, 2021

     116,433        8,440        3,734       585        2,484       131,676  
  

 

 

    

 

 

    

 

 

   

 

 

    

 

 

   

 

 

 

Accumulated amortization

               

At July 31, 2019

     1,601        —          1,269       66        29       2,965  

Amortization

     3,167        —          697       59        16       3,939  

Impairment

     106,189        2,000        —         —          —         108,189  
  

 

 

    

 

 

    

 

 

   

 

 

    

 

 

   

 

 

 

At July 31, 2020

     110,957        2,000        1,966       125        45       115,093  

Amortization

     384        —          521       44        94       1,043  

Disposals

     —          —          (872     —          —         (872
  

 

 

    

 

 

    

 

 

   

 

 

    

 

 

   

 

 

 

At April 30, 2021

     111,341        2,000        1,615       169        139       115,264  
  

 

 

    

 

 

    

 

 

   

 

 

    

 

 

   

 

 

 

Net book value

               

At July 31, 2019

     114,832        8,440        2,289       519        1,202       127,282  

At July 31, 2020

     5,476        6,440        1,744       460        1,888       16,008  
  

 

 

    

 

 

    

 

 

   

 

 

    

 

 

   

 

 

 

At April 30, 2021

     5,092        6,440        2,119       416        2,345       16,412  
  

 

 

    

 

 

    

 

 

   

 

 

    

 

 

   

 

 

 

Research and development expenses in the three and nine months ended April 30, 2021 were $730 and $2,901, respectively (April 30, 2020 - $1,017 and $3,962, respectively).

12. Convertible Debenture Receivable

On February 15, 2021 Zenabis entered into an agreement with HEXO for the issuance of an unsecured convertible debenture to the Company in a principal amount of $19,500. On this date, HEXO advanced Zenabis $12,500 in cash and converted the previous supply prepayment of $7,000 to a convertible debenture receivable. The debenture is convertible into common shares of Zenabis at a conversion price equal to the 5-day volume weighted average price (“VWAP”) of the Zenabis common shares on TSX for the five trading days prior to the date of conversion. The debenture may be prepaid by Zenabis, at its option and without penalty or premium. The unsecured convertible debenture bears interest at a rate of 8% per annum and matures on February 15, 2023.

Upon initial recognition of the $19,500 face value convertible debenture receivable (Level 2) on February 16, 2021, the fair value was derived using the calculated 5-day VWAP of $0.1724 and the closing market price of $0.18. The estimated fair value upon recognition was $20,360.

The fair value of the convertible debenture receivable as at April 30, 2021 was estimated using the calculated 5-day VWAP of $0.1174 and the closing market price of $0.12. The estimated fair value as at April 30, 2021 was $20,246. The gain on revaluation of the instrument was $434.

13. Warrant Liabilities

 

     USD$25,000
Registered Direct
Offering
     USD$20,000
Registered Direct
Offering
     Total  
     $      $      $  

Balance as at July 31, 2020

     1,917        1,533        3,450  

Loss on revaluation of financial instruments

     5,326        4,261        9,587  
  

 

 

    

 

 

    

 

 

 

Balance as at April 30, 2021

     7,243        5,794        13,037  
  

 

 

    

 

 

    

 

 

 

The warrants are classified as a liability because the exercise price is denominated in US dollars, which is different to the functional currency of the Company.

The warrant liabilities were revalued on April 30, 2021 using the Black-Scholes-Merton option pricing model (Level 2) using the following assumptions:

 

   

stock price of USD$6.70;

 

   

expected life of 2.5 years;

 

   

$nil dividends;

 

   

96.54% volatility based upon historical data;

 

   

risk-free interest rate of 0.29%; and

 

   

USD/CAD exchange rate of 1.2285.

 

9


USD$20,000 Registered Direct Offering – Warrants

On April 30, 2021 the Company had 1,497,007 common share purchase warrants outstanding (Note 18) with an exercise price of USD$9.80 per share with a five year-term.

The loss/(gain) on the revaluation of the warrant liability during the three and nine months ended April 30, 2021 was $170 and $4,261, respectively (April 30, 2020 – ($4,261) and ($3,071), respectively) which is recorded in Other income and losses on the consolidated statements of loss and comprehensive loss.

USD$25,000 Registered Direct Offering – Warrants

On April 30th, 2021 the Company had 1,871,259 common share purchase warrants outstanding (Note 18) with an exercise price of USD$9.80 per share with a five year- term.

The loss/(gain) on the revaluation of the warrant liability during the three and nine months ended April 30, 2021 was $212 and $5,326, respectively (April 30, 2020 – ($2,752) and ($4,508), respectively) which is recorded in Other income and losses on the consolidated statements of loss and comprehensive loss.

14. Convertible Debentures

 

Balance as at July 31, 2020

   $ 28,969  

Interest expense

     5,391  

Interest paid

     (2,409
  

 

 

 

Balance as at April 30, 2021

   $ 31,951  
  

 

 

 

On December 5, 2019, the Company closed a $70,000 private placement of convertible debentures. The Company issued a total of $70,000 principal amount of 8.0% unsecured convertible debentures maturing on December 5, 2022 (the “Debentures”). The Debentures are convertible at the option of the holder at any time after December 7, 2020 and prior to maturity at a conversion price of $12.64 per share (the “Conversion Price”), subject to adjustment in certain events. The Company may force the conversion of all of the then outstanding Debentures at the Conversion Price at any time after December 7, 2020 and prior to maturity on 30 days’ notice if the daily volume weighted average trading price of the common shares of the Company is greater than $30.00 for any 15 consecutive trading days.

The Company had the option to at any time on or before December 4, 2020, to repay all, but not less than all, of the principal amount of the Debentures, plus accrued and unpaid interest. Upon maturity, the holders of the Debentures have the right to require the Company to repay any principal amount of their Debentures through the issuance of common shares of the Company in satisfaction of such amounts at a price equal to the volume weighted average trading price of the common shares on the TSX for the five trading days immediately preceding the payment date.

In May 2020, the Company provided notice to all holders of the Debentures of an option to voluntarily convert their Debentures into units of the Company (the “Conversion Units”) at a discounted early conversion price of $0.80 (the “Early Conversion Price”) calculated based on the 5-day volume weighted average HEXO Corp. market prices (the “VWAP”) preceding the announcement. The VWAP unitized data from both the TSX and NYSE. Each Conversion Unit will provide the holder one common share and one half common share purchase warrant (with an exercise price of $4.00 and term of three years). The early conversion occurred in two phases, the first being on June 10, 2020 followed by the second and final phase June 30, 2020. During phases one and two, $23,595 principal amount, or approximately 34%, and $6,265 principal amount, or approximately 9% of the Debentures were converted under the Early Conversion Price into 7,373,438 and 1,957,813 common shares and 3,686,719 and 978,906 common share purchase warrants of HEXO Corp, respectively.

On April 30, 2021, there remains $40,140 in principal debentures, the net present value of the debt was $26,600 and the remaining balance of $13,540, was allocated to the conversion feature.

The accrued and unpaid interest as at April 30, 2020 was $483.

15. Lease Liabilities

The following is a continuity schedule of lease liabilities for the nine months ended April 30, 2021:

 

     $  

Balance as at July 31, 2020

     29,116  

Lease disposals

     (789

Lease payments

     (3,476

Interest expense on lease liabilities

     2,374  
  

 

 

 

Balance as at April 30, 2021

     27,225  
  

 

 

 

Current portion

     4,659  
  

 

 

 

Long-term portion

     22,566  
  

 

 

 

 

10


The Company’s leases consist of administrative real estate leases and a production real estate property. Effective August 1, 2020, the Company exited two real estate leases and the corresponding liability was written off for a realized a gain $181 recognized in Other income and losses on the consolidated statements of loss. The Company expensed variable lease payments of $815 and $2,412, respectively for the three and nine months ended April 30, 2021 (April 30, 2020 – $895 and $2,818, respectively).

The following table is the Company’s lease obligations over the next five fiscal years and thereafter as at April 30, 2021:

 

Fiscal year

   2021      2022 – 2023      2024 – 2025      Thereafter      Total  
     $      $      $      $      $  

Lease obligations

     1,143        9,186        8,749        31,082        50,160  

16. Term Loan

Term Loan

On February 14, 2019, the Company entered into a syndicated credit facility with Canadian Imperial Bank of Commerce (“CIBC”) as Sole Bookrunner, Co-Lead Arranger and Administrative Agent and Bank of Montreal as Co-Lead Arranger and Syndication Agent (together “the Lenders”). The Lenders provided the Company with up to $65,000 in secured debt financing at a rate of interest that is expected to average in the mid-to-high 5% per annum range. The credit facility consisted of an up to $50,000 term loan (“Term Loan”) and up to a $15,000 in a revolving credit facility which is limited to the Company’s working capital assets available to support funded balances. The credit facility had a maturity date of February 14, 2022 and was secured against the Company’s property, plant and equipment. The Company was to repay at minimum 2.5% of the initial amount drawn each quarter per the terms of the credit facility agreement. On February 14, 2019, the Company received $35,000 on the Term Loan and incurred financing costs of $1,347.

Under the terms of the credit facility the Company was able to repay the loan without penalty, at any time and did so, in full, on April 30, 2021.

On July 31, 2020 the Company was not in compliance with an administrative banking covenant which mandated that the Company does not utilize a Canadian dollar operating bank account with any institution other than the Lenders. The Company was subject to the covenant 90 days after entering the syndicated credit facility on February 14, 2019. The Company received an amendment on October 29, 2020 allowing it to rectify this administrative breach by April 27, 2021. Due to the amendment being received after July 31, 2020 and within the three months ended October 31, 2020 the Company classified its Term Loan as a current liability on July 31, 2020. On April 30, 2021, the Company repaid the credit facility in full and therefore is no longer subject to the credit facilities financial or administrative covenants. The credit facility has therefore been terminated and is no longer available to the Company.

In the nine months ended April 30, 2021, total interest expenses were $990 (April 30, 2020 - $567) and total interest capitalized was $419 (April 30, 2020 - $752). The non- cash interest expense relating to the amortization of deferred financing costs was $793 for the nine months ended April 30, 2021 (April 30, 2020 - $364).

The following table illustrates the continuity schedule of the term loan as at April 30, 2021 and July 31, 2020:

 

     April 30, 2021      July 31, 2020  
     $      $  

Term loan

     

Opening balance

     30,625        34,125  

Repayments

     (30,625      (3,500
  

 

 

    

 

 

 

Ending balance

     —          30,625  
  

 

 

    

 

 

 

Deferred financing costs

     $        $  

Opening balance

     (695      (751

Additions

     (98      (445

Amortization of deferred finance costs

     793        501  
  

 

 

    

 

 

 

Ending balance

     —          (695
  

 

 

    

 

 

 

Total term loan

     —          29,930  
  

 

 

    

 

 

 

Current portion

     —          29,930  
  

 

 

    

 

 

 

Long-term portion

     —          —    
  

 

 

    

 

 

 

17. Share Capital

(a) Authorized

An unlimited number of common shares and an unlimited number of special shares, issuable in series.

(b) Consolidation Announcement

The Company finalized the share consolidation on the basis of four pre-consolidation common shares for one post-consolidation common share (4:1) by way of shareholder approval at the annual and special meeting of shareholders held December 11, 2020 (the “Consolidation”). The Consolidation was effected by the filing of articles of amendment to the Company’s articles under the Business Corporations Act (Ontario) on December 18, 2020. The purpose of the proposed share consolidation is to increase the Company’s

 

11


common share price to regain compliance with the USD$1.00 minimum share price continued listing standard of the New York Stock Exchange.

All balances of common shares, common share purchase warrants, stock options and restricted share units herein are reflective of the Consolidation.

(c) Issued and Outstanding

As at April 30, 2021, a total of 122,465,538 (July 31, 2020 – 120,616,441) common shares were issued and outstanding. No special shares have been issued or are outstanding.

 

            Number of shares      Share Capital  

Balance at July 31, 2020

        120,616,441      $ 1,023,788  

June 2020 at the market offering

     (i      244,875        —    

Exercise of warrants

        1,522,139        7,430  

Exercise of stock options

        82,083        499  

Issuance fees

        —          (192
     

 

 

    

 

 

 

Balance at April 30, 2021

        122,465,538      $ 1,031,525  
     

 

 

    

 

 

 

 

(i)

June 2020 At-the-market (“ATM”) Offering

On June 16, 2020, the Company established an ATM equity program allowing the Company to issue up to $34,500 (or its U.S. dollar equivalent) of common shares to the public. The common shares sold through the ATM program were sold through the TSX, the NYSE and other marketplaces on which the common shares were listed, quoted or otherwise traded, at the prevailing market price at the time of sale. The program closed on July 31, 2020 and a total of approximately $34,551 (after foreign exchange gains) was generated through the issuance of 8,235,620 common shares in the year ended July 31, 2020. On July 31, 2020 a receivable of $883 remained for irrevocable sales which occurred prior to year end and subsequently settled on August 5, 2020, at which time the remaining 244,875 shares were issued.

18. Common Share Purchase Warrants

The following table summarizes warrant activity during the nine months ended April 30, 2021 and year ended July 31, 2020.

 

     April 30, 2021      July 31, 2020  
     Number of      Weighted average      Number of      Weighted average  
     warrants      exercise price1      warrants      exercise price1  

Outstanding, beginning of year

     33,379,408      $ 7.60        7,396,359      $ 39.80  

Expired

     (97,123      3.92        (3,889,871      49.00  

Issued

     —          —          30,976,389        4.96  

Exercised

     (1,522,139      3.85        (1,103,469      3.88  
  

 

 

    

 

 

    

 

 

    

 

 

 

Outstanding, end of year

     31,760,146      $ 7.66        33,379,408      $ 7.60  
  

 

 

    

 

 

    

 

 

    

 

 

 

 

1 

USD denominated warrant’s exercise price have been converted to the CAD equivalent as at the period end for presentation purposes.

The 97,123 expired and cancelled warrants during the nine months ended April 30, 2021 were due to cashless exercises of the Company’s April 2020 and May 2020 warrants. In lieu of cash equal to the number of warrants exercised multiplied by the exercise price, the warrant holder forgoes the corresponding number of warrants which are effectively cancelled.

The following is a consolidated summary of warrants outstanding as at April 30, 2021 and July 31, 2020.

 

     April 30, 2021      July 31, 2020  
     Number
outstanding
     Book value      Number
outstanding
     Book value  

Classified as Equity

      $           $    

June 2019 financing warrants

           

Exercise price of $63.16 expiring June 19, 2023

     546,135        10,022        546,135        10,022  

April 2020 underwritten public offering warrants

           

Exercise price of $3.84 expiring April 13, 2025

     12,459,750        16,821        14,004,375        18,906  

May 2020 underwritten public offering warrants

           

Exercise price of $4.20 expiring May 21, 2025

     7,777,876        10,702        7,852,513        10,805  

Conversion Unit warrants

           

Exercise price of $4.00 expiring June 10, 2023

     3,686,721        11,426        3,686,721        11,426  

Exercise price of $4.00 expiring June 30, 2023

     978,907        1,928        978,907        1,928  

Broker / Consultant warrants

           

Exercise price of $3.00 expiring November 3, 2021

     43,905        78        43,905        78  

Exercise price of $3.00 expiring March 14, 2022

     23,571        66        23,571        66  

Exercise price of $63.16 expiring June 19, 2023

     15        —          15        —    

Molson warrants

           

 

12


     April 30, 2021      July 31, 2020  
     Number
outstanding
     Book value      Number
outstanding
     Book value  

Exercise price of $24.00 expiring October 4, 2021

     2,875,000        42,386        2,875,000        42,386  
  

 

 

    

 

 

    

 

 

    

 

 

 
     28,391,880        93,429        30,011,142        95,617  

Classified as Liability

           

USD$25m Registered Direct Offering Warrants

           

Exercise price of USD$9.80 expiring December 31, 2024

     1,871,259        7,243        1,871,259        1,917  

USD$20m Registered Direct Offering Warrants

           

Exercise price of USD$9.80 expiring January 22, 2025

     1,497,007        5,794        1,497,007        1,533  
  

 

 

    

 

 

    

 

 

    

 

 

 
     3,368,266        13,037        3,368,266        3,450  
  

 

 

    

 

 

    

 

 

    

 

 

 
     31,760,146        106,466        33,379,408        99,067  
  

 

 

    

 

 

    

 

 

    

 

 

 

19. Share-based Compensation

Stock Options

The following table summarizes stock option activity during the nine months ended April 30, 2021 and the year ended July 31, 2020.

 

     April 30, 2021      July 31, 2020  
     Number of
options
     Weighted average
exercise price
     Number of
options
     Weighted average
exercise price
 

Opening balance

     7,503,689      $ 16.30        6,072,243      $ 23.48  

Granted

     2,091,172        5.03        2,986,507        6.48  

Forfeited

     (593,408      13.03        (1,145,610      22.20  

Expired

     (462,550      27.82        (380,318      26.64  

Exercised

     (82,083      3.70        (29,133      4.60  
  

 

 

    

 

 

    

 

 

    

 

 

 

Closing balance

     8,456,820      $ 13.23        7,503,689      $ 16.30  
  

 

 

    

 

 

    

 

 

    

 

 

 

The following table summarizes the stock option grants during the nine months ended April 30, 2021.

 

            Options granted                

Grant date

   Exercise
price ($)
     Executives and
directors
     Non-executive
employees
     Total      Vesting terms      Expiry period  

October 30, 2020

     3.88        349,652        315,358        665,010        Terms A        10 years  

December 22, 2020

     5.44        380,673        960,100        1,340,773        Terms A        10 years  

April 28, 2021

     7.54        —          85,389        85,389        Terms A        10 years  
     

 

 

    

 

 

    

 

 

       

Total

        730,325        1,360,847        2,091,172        
     

 

 

    

 

 

    

 

 

       

Vesting terms A – One-third of the options will vest on each of the one-year anniversaries of the date of grant over a three-year period.

The following table summarizes information concerning stock options outstanding as at April 30, 2021.

 

Exercise price

   Number
outstanding
     Weighted average
remaining life (years)
     Number
exercisable
     Weighted average
remaining life (years)
 

$2.32–$10.76

     4,566,444        8.86        943,941        6.78  

$15.56–$26.16

     1,664,895        8.00        1,051,887        7.78  

$28.52–$34.00

     2,220,732        7.65        1,205,879        7.53  

$47.36–$66.96

     4,749        0.41        4,749        0.41  
  

 

 

       

 

 

    
     8,456,820           3,206,456     
  

 

 

       

 

 

    

Restricted Share Units (“RSUs”)

Under the Omnibus Plan, the Board of Directors is authorized to issue RSUs up to 10% of the issued and outstanding common shares, inclusive of the outstanding stock options. At the time of issuance, the Board of Directors establishes conversion values and expiry dates, which are up to 10 years from the date of issuance. The restriction criteria of the units are at the discretion of the Board of Directors and from time to time may be inclusive of Company based performance restrictions, employee-based performance restrictions or no restrictions to the units.

The following table summarizes RSU activity during the nine months ended April 30, 2021 and the year ended July 31, 2020.

 

13


     April 30, 2021      July 31, 2020  
            Value of units on             Value of units on  
     Units      grant date      Units      grant date  

Opening balance

     587,108      $ 8.41        —        $ —    

Granted

     7,161        3.16        609,636        8.52  

Exercised

     (25,483      8.60        —          —    

Forfeited

     (34,801      11.76        (22,528      11.76  
  

 

 

    

 

 

    

 

 

    

 

 

 

Closing balance

     533,985      $ 7.96        587,108      $ 8.41  
  

 

 

    

 

 

    

 

 

    

 

 

 

The following table summarizes the RSUs granted during the nine months ended April 30, 2021.

 

            RSUs granted                

Grant date

   Unit value      Executive and
directors
     Non-executive
employees
     Vesting
terms
     Expiry
period
 

October 30, 2020

   $ 3.16        7,161        —          Terms A        10 years  
     

 

 

          

Total

        7,161           
     

 

 

          

Vesting terms A – One-third of the units vest on each of the one-year anniversaries for the first three years after the grant date.

Share-based Compensation

Share-based compensation is measured at fair value at the date of grant and are expensed over the vesting period (See Note 22 for share-based compensation allocation by expense group). In determining the amount of share-based compensation, the Company used the Black-Scholes-Merton option pricing model to establish the fair value of stock options and RSUs granted at grant date by applying the following assumptions:

 

     April 30, 2021     July 31, 2020  

Exercise price (weighted average)

   $ 17.97     $ 26.04  

Market price (weighted average)

   $ 18.16     $ 26.44  

Risk-free interest rate (weighted average)

     1.30     1.79

Expected life (years) of options (weighted average)

     5       5  

Expected annualized volatility (weighted average)

     83     75

Volatility was estimated using the average historical volatility of the Company and comparable companies in the industry that have trading history and volatility history.

For the three and nine months ended April 30, 2021, the Company allocated to inventory $444 and $1,284, respectively (April 30, 2020 – $1,358 and $5,088) of share-based compensation applicable to direct and indirect labour in the cultivation and production process..     

The cash-settled share-based compensation liability is presented in Other liabilities. The following table summarizes the Company’s equity-settled and cash-settled share- based payments for the nine months ended April 30, 2021 and 2020.

 

     April 30, 2021      April 30, 2020  
     $        $  

Stock option share-based compensation

     10,337        18,599  

RSU share-based compensation

     —          —    
  

 

 

    

 

 

 

Total equity-settled share-based compensation

     10,337        18,599  
  

 

 

    

 

 

 

RSU share-based compensation

     1,850        —    
  

 

 

    

 

 

 

Total cash-settled share-based compensation

     1,850        —    
  

 

 

    

 

 

 

 

14


20. Net Loss per Share

The following securities could potentially dilute basic net loss per share in the future but have not been included in diluted loss per share because their effect was anti-dilutive:

 

Instrument

   April 30, 2021      July 31, 2020  

Stock Options

     8,456,820        7,503,690  

RSUs

     533,985        587,108  

2019 June financing warrants

     546,135        546,135  

USD$25m registered direct offering warrants

     1,871,259        1,871,259  

USD$20m registered direct offering warrants

     1,497,007        1,497,007  

2020 April underwritten public offering warrants

     12,459,750        14,004,375  

2020 May underwritten public offering warrants

     7,777,876        7,852,513  

Warrants issued under conversion of debentures

     4,665,628        4,665,628  

Joint venture and Inner Spirit issued warrants

     2,875,000        2,875,000  

Convertible debenture broker/finder warrants

     67,491        67,491  
  

 

 

    

 

 

 
     40,750,951        41,470,206  
  

 

 

    

 

 

 

21. Financial Instruments

Market Risk

Interest Risk

The Company has minimal exposure to interest rate risk related to any investments of cash and cash equivalents. The Company may invest cash in highly liquid investments with short terms to maturity that would accumulate interest at prevailing rates for such investments. As at April 30, 2021, the Company had no term loans (July 31, 2020 – $29,930) (Note 16).

Price Risk

Price risk is the risk of variability in fair value due to movements in equity or market prices. The Company’s level 1 and 2 investments are susceptible to price risk arising from uncertainties about their future outlook, future values and the impact of market conditions. The fair value of marketable securities and derivatives held in publicly traded entities is based on quoted market prices, which the shares of the investments can be exchanged for. The Company elected an early conversion option in the year ended July 31, 2020 in which $29,860 of the aggregate principal amount of its 8% unsecured convertible debentures (Note 14) were converted, which partially mitigates the Company’s Price Risk.

There would be no material impact (July 31, 2020 – no material impact) if the fair value of these financial assets were to increase or decrease by 10% as of April 30, 2021. The price risk exposure as at April 30, 2021 and July 31, 2020 is presented in the table below.

 

     April 30, 2021      July 31, 2020  
     $        $  

Financial assets

     4,402        2,692  

Financial liabilities

     (13,037      (3,450
  

 

 

    

 

 

 

Total exposure

     (8,635      (758
  

 

 

    

 

 

 

Credit Risk

Credit risk is the risk of financial loss to the Company if a customer or counterparty to a financial instrument fails to meet its contractual obligations and arises principally from the Company’s trade receivables and convertible debentures receivable. As at April 30, 2021, the Company was exposed to credit related losses in the event of non-performance by the counterparties.

The Company provides credit to its customers in the normal course of business and has established credit evaluation and monitoring processes to mitigate credit risk. Since the majority of the medical sales are transacted with clients that are covered under various insurance programs, and adult use sales are transacted with crown corporations, the Company has limited credit risk.

Cash and cash equivalents, certain restricted funds and short-term investments are held with four Canadian commercial banks that hold Dun and Bradstreet credit ratings of AA (July 31, 2020 – AA) and $111 is held with a credit union that does not have a publicly available credit rating. Certain restricted funds in the amount of $30,000 are managed by an insurer and are held as a cell captive within a Bermuda based private institution which does not have a publicly available credit rating; however the utilized custodian is Citibank which holds a credit rating of A+. The majority of the trade receivables balance is held with crown corporations of Quebec, Ontario and Alberta. Creditworthiness of a counterparty is evaluated prior to the granting of credit. The Company has estimated the expected credit loss using a lifetime credit loss approach. The current expected credit loss for the nine months ended April 30, 2021 is $36 (July 31, 2020 - $35).

 

15


In measuring the expected credit losses, the adult-use cannabis trade receivables have been assessed on a per customer basis as they consist of a low number of material contracts. Medical trade receivables have been assessed collectively as they have similar credit risk characteristics. They have been grouped based on the days past due.

Credit risk from the convertible debenture receivable arises from the possibility that principal and/or interest due may become uncollectible. The Company mitigates this risk by managing and monitoring the underlying business relationship.

The carrying amount of cash and cash equivalents, restricted cash and trade receivables represents the maximum exposure to credit risk and as at April 30, 2021; this amounted to$132,638 (July 31, 2020 – $211,860).

The following table summarizes the Company’s aging of trade receivables as at April 30, 2021 and July 31, 2020:

 

     April 30,
2021
     July 31,
2020
 
     $        $  

0–30 days

     14,830        15,253  

31–60 days

     2,407        2,972  

61–90 days

     375        412  

Over 90 days

     1,437        789  
  

 

 

    

 

 

 

Total

     19,049        19,426  
  

 

 

    

 

 

 

Economic Dependence Risk

Economic dependence risk is the risk of reliance upon a select number of customers, which significantly impacts the financial performance of the Company. For the three months ended April 30, 2021, the Company’s recorded sales to the crown corporations; Société québécoise du cannabis (“SQDC”) the Ontario Cannabis Store (“OCS”) and the Alberta Gaming, Liquor and Cannabis agency (“ALGC”) representing 44%, 26% and 15%, respectively (April 30, 2020 – one crown corporation representing 83%) of total applicable periods gross cannabis sales.

For the nine months ended April 30, 2021, the Company’s recorded sales to the crown corporations; Société québécoise du cannabis (“SQDC”) the Ontario Cannabis Store (“OCS”) and the Alberta Gaming, Liquor and Cannabis agency (“ALGC”) representing 50%, 20% and 17%, respectively (April 30, 2020 – one crown corporation representing 75%) of total applicable periods gross cannabis sales.

The Company holds trade receivables from the crown corporations SQDC, OCS and the AGLC representing 30%, 35% and 14%, respectively, of total trade receivable, respectively as at April 30, 2021 (July 31, 2020 – two crown corps SQDC and OCS representing 47% and 25% of total trade receivables, respectively).

Liquidity Risk

Liquidity risk is the risk that the Company will not be able to meet its financial obligations as they come due. The Company manages its liquidity risk by reviewing on an ongoing basis its capital requirements. As at April 30, 2021, the Company had $81,038 (July 31, 2020 –$184,173) of cash and cash equivalents and $19,049 (July 31, 2020 –$19,426) in trade receivables.

The Company has current liabilities of $69,742 and contractual commitments of $9,472 due before July 31, 2022. The Company’s existing cash and cash equivalents and trade receivables are expected to provide sufficient liquidity to meet cash outflow requirements over the next twelve months.

The Company’s success in executing on its longer-term strategy is dependent upon its ability to fund the repayment of existing borrowings and to generate positive cash flows from operations. If additional liquidity is required, management plans to secure the necessary financing through the issuance of new public or private equity or debt instruments. There is no assurance that additional future funding will be available to the Company, or that it will be available on terms which are acceptable to management.

The carrying values of cash and cash equivalents, trade receivables and accounts payable and accrued liabilities approximate their fair values due to their short-term to maturity.

Foreign Currency Risk

On April 30, 2021, the Company holds certain financial assets and liabilities denominated in United States Dollars (“USD”) which consist of cash and cash equivalents, and warrant liabilities. The Company does not currently use foreign exchange contracts to hedge its exposure of its foreign currency cash flows as management has determined that this risk is not significant. The Company closely monitors relevant economic information to minimize its net exposure to foreign currency risk. The Company is exposed to unrealized foreign exchange risk through its cash and cash equivalents. As at April 30, 2021, approximately $35,614 (USD$29,492) (July 31, 2020 – $42,981 (USD$57,652)) of the Company’s cash and cash equivalents was in USD. A 1% change in the foreign exchange rate would result in a change of $356 to the unrealized gain or loss on foreign exchange or on the gain or loss on financial instrument revaluation of USD denominated warrants.

 

16


22. Operating Expenses by Nature

The following table disaggregates the selling, general and administrative expenses as presented on the Statement of Loss and Comprehensive Loss into specified classifications based upon their nature:

 

     For the three months ended      For the nine months ended  
     April 30,
2021
     April 30,
2020
     April 30,
2021
     April 30,
2020
 
     $        $        $        $  

Salaries and benefits

     3,448        2,633        13,711        8,657  

Professional fees

     3,023        1,924        8,523        7,534  

Facilities

     1,348        1,996        3,822        5,398  

Selling, general and administrative

     5,940        2,947        9,979        11,284  

Consulting

     1,019        1,447        2,791        6,044  

Travel

     44        291        213        1,916  
  

 

 

    

 

 

    

 

 

    

 

 

 

Total

     14,822        11,238        39,039        40,833  
  

 

 

    

 

 

    

 

 

    

 

 

 

The following table summarizes the nature of share-based compensation in the period:

 

     For the three months ended      For the nine months ended  
     April 30,
2021
     April 30,
2020
     April 30,
2021
     April 30,
2020
 
     $      $      $      $  

General and administrative related share-based compensation

     2,502        5,941        10,323        21,543  

Marketing and promotion related share-based compensation

     213        230        581        694  
  

 

 

    

 

 

    

 

 

    

 

 

 

Total operating expense related share-based compensation

     2,715        6,171        10,904        22,237  

Share based compensation capitalized to inventory

     444        1,357        1,283        5,089  
  

 

 

    

 

 

    

 

 

    

 

 

 

Total share-based compensation

     3,159        7,528        12,187        27,326  
  

 

 

    

 

 

    

 

 

    

 

 

 

The following table summarizes the total payroll related wages and benefits by nature in the period:

 

     For the three months ended      For the nine months ended  
     April 30,
2021
     April 30,
2020
     April 30,
2021
     April 30,
2020
 
     $      $      $      $  

General and administrative related wages and benefits

     3,448        2,633        13,711        8,657  

Marketing and promotion related wages and benefits

     1,560        1,148        4,064        3,796  

Research and development related wages and benefits

     433        513        2,247        2,226  
  

 

 

    

 

 

    

 

 

    

 

 

 

Total operating expense related wages and benefits

     5,441        4,294        20,022        14,679  

Wages and benefits capitalized to inventory

     3,465        3,991        11,795        17,317  
  

 

 

    

 

 

    

 

 

    

 

 

 

Total wages and benefits

     8,906        8,285        31,817        31,996  
  

 

 

    

 

 

    

 

 

    

 

 

 

23. Other Income and Losses

 

     For the three months ended      For the nine months ended  
     April 30,
2021
     April 30,
2020
     April 30,
2021
     April 30,
2020
 
     $      $      $      $  

Interest and financing expenses

     (3,296      (3,279      (8,368      (7,312

Interest income

     349        353        1,057        1,239  
  

 

 

    

 

 

    

 

 

    

 

 

 

Finance income (expense), net

     (2,947      (2,926      (7,311      (6,073
  

 

 

    

 

 

    

 

 

    

 

 

 

Revaluation of financial instruments gain

     (383      4,955        (9,587      7,966  

Share of loss from investment in associate and joint ventures

     (2,244      (1,195      (5,902      (4,468

Loss on convertible debenture receivable

     746        (212      746        (3,253

Unrealized gain/(loss) on investments

     544        (311      1,204        (8,535

Realized gain on investments

     —          (1,217      —          (1,444

Foreign exchange gain/(loss)

     (1,514      2,443        (3,836      3,017  

Other income

     1,177        —          4,511        —    
  

 

 

    

 

 

    

 

 

    

 

 

 

Non-operating income (expense), net

     (1,674      4,463        (12,864      (6,717
  

 

 

    

 

 

    

 

 

    

 

 

 

 

17


24. Related Party Disclosure

Compensation of Key Management

Key management personnel are those persons having the authority and responsibility for planning, directing and controlling the Company’s operations, directly or indirectly. The key management personnel of the Company are the members of the executive management team and Board of Directors.

Compensation provided to key management during the year was as follows:

 

     For the three months ended      For the nine months ended  
     April 30,
2021
     April 30,
2020
     April 30,
2021
     April 30,
2020
 
     $      $      $      $  

Salary and/or consulting fees

     764        715        1,846        2,365  

Termination benefits

     —          427        1,008        427  

Bonus compensation

     210        —          620        42  

Stock-based compensation

     1,454        4,302        5,709        13,894  
  

 

 

    

 

 

    

 

 

    

 

 

 

Total

     2,428        5,444        9,183        16,728  
  

 

 

    

 

 

    

 

 

    

 

 

 

Related Parties and Transactions

Belleville Complex Inc.

The Company holds a 25% interest in Belleville Complex Inc. (“BCI”) with the related party Olegna Holdings Inc., a company owned and controlled by a director of the Company, holding the remaining 75% in BCI. BCI purchased a configured 2,004,000 sq. ft. facility through a $20,279 loan issued and repaid during the year ended July 31, 2019. The Company will be the anchor tenant for a 15-year, with an option to renew for 15 years and additional space to rent. The Company has also subleased a portion of the space to Truss Limited Partnership (Note 8). Consideration for the 25% interest on the joint venture is deemed $nil. The carrying value of BCI as at April 30, 2021 is $479 (July 31, 2020 - $nil).

The Company leases a space in Belleville from a related party BCI, that supports its manufacturing activities and is based in Belleville, Ontario. Under this lease arrangement, the Company incurred $1,261 and $3,427 in lease and operating expenses during the three and nine months ended April 30, 2021, respectively (April 30, 2020 - $1,236 and $5,510). This lease liability is recognized on the Company’s balance sheet under IFRS 16 (Note 15).

Truss LP

The Company owns a 42.5% interest in Truss LP and accounts for the interest as an investment in an associate (Note 9).

The Company subleases section of its Belleville lease to Truss LP this sublease is recognized as a finance lease receivable on the Company’s balance sheet (Note 5). The Company recognizes a recovery on its partnership with Truss LP in Other receivables and Other income.

Under a Temporary Supply and Services Agreement (“TSSA”) with Truss LP, the Company produces and packages cannabis infused beverages in the CIB Facility (located at the Belleville Facility) and in the Gatineau Facility, an markets and sells beverages for the legal adult-use markets in Canada, in each case subject to the terms of its regulatory approvals and applicable laws, all for its own account and as a stand-alone division of HEXO. Truss LP applied to be a licensed producer of Cannabis during the period, but until the time where Truss LP obtains all regulatory approval required under the Cannabis Act (Canada), the TSSA will remain in place. Under the TSSA, Truss LP will be an exclusive supplier to the Company of all property and all services required to carry on the business, other than specific services which are required to be provided by HEXO. As a result of this arrangement, there is a receivable from Truss of $1,908 at April 30, 2021 (July 31, 2020 – $3,405). During the three and nine months ended April 30, 2021, the Company purchased $782 and $5,955 (April 30, 2020 – $nil and $nil) of raw materials from Truss LP under the arrangement and received $1,045 (April 30, 2020 – $nil) of Income.

25. Capital Management

The Company’s objectives when managing capital are to (1) safeguard their ability to continue as a going concern, so that they can continue to provide returns for shareholders and benefits for other stakeholders, and (2) maintain an optimal capital structure to reduce the cost of capital.

Management defines capital as the Company’s shareholders’ equity and interest-bearing debt. The Board of Directors does not establish quantitative return on capital criteria for management. The Company has not paid any dividends to its shareholders. The Company is not subject to any externally imposed capital requirements, with the exception of covenants related to the Company’s Term Loan as set out in Note 16.

As at April 30, 2021, total managed capital was $527,125 (July 31, 2020 – $556,676).

 

18


26. Commitments and Contingencies

COMMITMENTS

The Company has certain contractual financial obligations related to service agreements, purchase agreements, rental agreements and construction contracts.

Some of these contracts have optional renewal terms that the Company may exercise at its option. The annual minimum payments payable under these obligations over the next five fiscal years and thereafter are as follows:

 

July 31, 2022

   $ 9,472  

July 31, 2023

     5,050  

July 31, 2024

     3,677  

July 31, 2025

     3,531  

July 31, 2026

     2,429  

Thereafter

     19,274  
  

 

 

 
   $  43,433  
  

 

 

 

See Note 15 for recognized contractual commitments regarding the Company’s lease obligations under IFRS 16.

LETTERS OF CREDIT

On August 21, 2019, the Company entered into a five-year letter of credit with a Canadian financial institution to provide a maximum of $250 that amortizes $50 annually until its expiry on July 14, 2024. The letter of credit has not been drawn upon as at April 30, 2021. As at April 30, 2021, the $200 letter of credit is secured by cash held in collateral (Note 4).

On August 1, 2020, the Company reissued a pre-existing letter of credit with a Canadian financial institution under an agreement with a public utility provider entitling the utility provider to a maximum of $2,581, subject to certain operational requirements. The letter of credit has a one-year expiry from the date of issuance with an autorenewal feature. On January 1, 2021, the letter of credit was reduced to $2,352 by way of amendment. The letter of credit has not been drawn upon as at April 30, 2021. The letter of credit is secured by cash held in collateral (Note 4).

CONTINGENCIES

The Company may be, from time to time, subject to various administrative and other legal proceedings arising in the ordinary course of business. Contingent liabilities associated with legal proceedings are recorded when a liability is probable, and the contingent liability can be reasonably estimated.

As of April 30, 2021, the Company is named as a defendant in securities class actions that have been filed in the superior court of the province of Quebec and in the Supreme Court of the State of New York. One or more of the Company’s current and/or former officers and directors, and/or certain underwriters of past public offerings by the Company, are also named as defendants in certain of the actions. The lawsuits assert causes of action under Canadian and U.S. securities legislation in connection with statements made by the defendants that are alleged to have been materially false and/or misleading statements and their alleged failure to disclose material adverse facts. The alleged misrepresentations relate to, among other things, the Company’s forward-looking information, including but not limited to the Company’s forecast revenues for Q4 2019 and fiscal 2020, its inventory, “channel stuffing” and the Company’s supply agreement with the Province of Quebec. As at the date hereof, the amounts claimed for damages in each of these actions have not been quantified. These actions are in a preliminary stage and have not yet been certified as class actions. In November 2020, the Superior Court of Justice of Ontario ordered the discontinuance of two putative securities class actions commenced in Ontario relating to the same matters on a without costs basis. On March 9, 2021, the United States District Court for the Southern District of New York dismissed the U.S. federal securities class action pending against the company relating to the same matters on a without costs basis, with the dismissal not having been appealed from.

As of April 30, 2021, the Company was named as a defendant in a proposed consumer protection class action filed on June 18, 2020 in the Court of Queens’ Bench in Alberta on behalf of residents of Canada who purchased cannabis products over specified periods of time. Several other licensed producers are also named as co-defendants in the action. The lawsuit asserts causes of action, including for breach of contract and breach of consumer protection legislation, arising out of allegations that the Tetrahydrocannabinol (THC) or Cannabidiol (CBD) content of medicinal and recreational cannabis products sold by the Company and the other defendants to consumers was different from what was advertised on the products’ labels. Many of the cannabis products sold by the Company and other defendants were allegedly sold to consumers in containers using plastic bottles or caps that may have rapidly absorbed or degraded the THC or CBD content within them. By allegedly over-representing the true amount of THC or CBD in the products, the plaintiff claims that consumers would be required to consume substantially more product than they otherwise would have in order to obtain the desired effects or, in the alternative, would have consumed the product without obtaining the desired effects. The action has not yet been certified as a class action.

ONEROUS CONTRACT

During the year ended July 31, 2020, the Company recognized a $4,763 onerous contract provision related to a fixed price supply agreement for the supply of certain cannabis products. The supply agreement is currently the subject of legal proceedings as disclosed above. The costs and purchase obligations under the contract exceed the economic benefits expected to be received. The related loss has been included in Other gains and losses. The onerous contract liability remains as at April 30, 2021.

 

19


27. Fair Value of Financial Instruments

The carrying values of the financial instruments as at April 30, 2021 are summarized in the following table:

 

     Amortized                
     cost      FVTPL      Total  

Assets

     $        $        $  

Cash and cash equivalents

     81,038        —          81,038  

Restricted funds

     32,551        —          32,551  

Trade receivables

     19,049        —          19,049  

Convertible debenture receivable

     —          20,246        20,246  

Commodity taxes recoverable and other receivables

     10,202        —          10,202  

Lease receivable – long term

     3,795        —          3,795  

Long – term investments

     —          4,402        4,402  
  

 

 

    

 

 

    

 

 

 

Liabilities

     $        $        $  

Accounts payable and accrued liabilities

     42,968        —          42,968  

Warrant liability

     —          13,037        13,037  

Lease liability – current

     4,659        —          4,659  

Lease liability – long term

     22,566        —          22,566  

Convertible debentures

     31,951        —          31,951  

Term loan – current

     —          —          —    

Other long-term liabilities(1)

     —          1,805        1,805  
  

 

 

    

 

 

    

 

 

 

 

1 

Financial liability designated as FVTPL.

The carrying values of the financial instruments as at July 31, 2020 are summarized in the following table:

 

     Amortized                
     cost      FVTPL      Total  

Assets

     $        $        $  

Cash and cash equivalents

     184,173        —          184,173  

Restricted funds

     8,261        —          8,261  

Trade receivables

     19,426        —          19,426  

Commodity taxes recoverable and other receivables

     16,773        —          16,773  

Lease receivable – long term

     3,865        —          3,865  

Long – term investments

     —          3,209        3,209  
  

 

 

    

 

 

    

 

 

 

Liabilities

     $        $        $  

Accounts payable and accrued liabilities

     32,451        —          32,451  

Warrant liability

     —          3,450        3,450  

Lease liability – current

     4,772        —          4,772  

Lease liability – long term

     24,344        —          24,344  

Convertible debentures

     28,969        —          28,969  

Term loan – current

     29,930        —          29,930  

Other long-term liabilities(1)

     —          393        393  
  

 

 

    

 

 

    

 

 

 

 

1 

Financial liability designated as FVTPL.

The carrying values of cash and cash equivalents, restricted funds, short term investments, trade and other receivables, lease receivables, accounts payable and accrued liabilities, lease liabilities and term loan approximate their fair values due to their relatively short periods to maturity.

28. Non-Controlling Interest

The following table summarizes the information relating to the Company’s non-controlling interests, before intercompany eliminations.

 

     April 30, 2021     July 31, 2020  

Current assets

   $ —       $ —    

Non-current assets

     8,448       7,455  

Current liabilities

     —         —    

Non-current liabilities

     —         —    
  

 

 

   

 

 

 

Non-controlling interest (%)

     40     40
  

 

 

   

 

 

 

Non-controlling interest

   $ 3,379     $  3,379  
  

 

 

   

 

 

 

The Company holds a 60% interest in Keystone Isolation Technology Inc. (“KIT”) which is intended to principally operate out of Belleville Facility, and the remaining 40% represents the non-controlling interest held by Chroma Global Technologies Ltd (the “Partner”). Under the terms of the shareholder agreement, the Company has contributed cash of $4,699 (USD$3,100). The non-controlling interest value of $3,750 represents the value of the Partners contribution in kind for their respective equity interest in the

 

20


entity. During the three months ended October 31, 2020, the Partner contributed capital equipment in-kind of $371 as required under the terms of the shareholders agreement. There remains approximately $325 of an in-kind commissioning contribution to satisfy the acquisition terms of the shareholders agreement. KIT had no revenues or expenses during the nine months ended April 30, 2021 and the year ended July 31, 2020.

29. Revenue from Sale of Goods

The Company disaggregated its revenues from the sale of goods between sales of cannabis beverages (“Cannabis beverage sales”) and dried flower, vapes, and other cannabis products (“Cannabis sales excluding beverages”). The Company’s cannabis beverage sales are derived from the Cannabis Infused Beverage (“CIB”) line, which was established in order to manufacture, produce and sell cannabis beverage products. CIB operates under the Company’s cannabis licensing and in compliance with Health Canada and the Cannabis Act’s regulations. The Company has assessed the beverage revenue stream to be realized by the Company and presented on a gross basis as defined under IFRS 15. The Company will continue to operate CIB until Truss has obtained its independent licensing to manufacture and sell cannabis products, at which point these operations will shift to Truss.

 

For the three months ended

   April 30, 2021      April 30, 2020  

Revenue stream

   Cannabis sales
excluding
beverages
     Cannabis
beverage
sales
     Total      Cannabis sales
excluding
beverages
     Cannabis
beverage
sales
     Total  
     $      $      $      $      $      $  

Retail

     29,273        3,330        32,603        29,316        465        29,781  

Medical

     430        —          430        774        —          774  

Wholesale

     49        —          49        340        —          340  

International

     —          —          —          —          —          —    
  

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

 

Total revenue from sale of goods

     29,752        3,330        33,082        30,430        —          30,895  
  

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

 

 

For the nine months ended

   April 30, 2021      April 30, 2020  

Revenue stream

   Cannabis sales
excluding
beverages
     Cannabis
beverage
sales
     Total      Cannabis sales
excluding
beverages
     Cannabis
beverage
sales
     Total  
     $      $      $      $      $      $  

Retail

     104,587        10,280        114,867        70,549        465        71,014  

Medical

     1,508        —          1,508        2,655        —          2,655  

Wholesale

     559        —          559        340        —          340  

International

     3,125        —          3,125        —          —          —    
  

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

 

Total revenue from sale of goods

     109,779        10,280        120,059        73,544        —          74,009  
  

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

 

Total revenue from the sale of goods is presented net of provisions for sales returns and price concessions. During the three and nine months ended April 30, 2021 the Company incurred $936 and $2,474 (April 30, 2020—$1,950 and $5,370) of net sales provisions and price concessions, respectively.

30. Segmented Information

The Company operates under one material operating segment. All property, plant and equipment and intangible assets are located in Canada.

31. Operating Cash Flow

The following items comprise the Company’s operating cash flow activity for the periods herein.

 

For the nine months ended

   April 30, 2021      April 30, 2020  
     $      $  

Items not affecting cash

     

Income tax recovery

     —          (6,023

Depreciation of property, plant and equipment

     4,369        4,890  

Depreciation of property, plant and equipment in cost of sales

     1,502        2,313  

Amortization of intangible assets

     1,043        3,690  

Loss/(gain) on convertible debentures

     (746      3,253  

Unrealized gain on changes in fair value of biological assets

     (35,616      (21,378

Unrealized fair value adjustment on investments

     (1,204      8,535  

Amortization of deferred financing costs

     793        —    

Accrued interest income

     4,890        6,850  

Accretion of convertible debenture

     2,956        —    

Gain/(Loss) on investment

     —          1,444  

License depreciation and prepaid royalty expenses

     118        301  

Write-off of inventory and biological assets

     1,001        2,838  

Write (up)/down of inventory to net realizable value

     —          39,311  

Realized fair value amounts on inventory sold

     17,619        21,362  

 

21


For the nine months ended

   April 30, 2021      April 30, 2020  

Loss from investment in associate and joint ventures

     5,902        4,468  

Share-based compensation

     12,000        22,237  

Revaluation of financial instruments (gain)/loss

     9,587        (7,966

Impairment losses

     (662      251,070  

Loss on onerous contract

     —          3,000  

Loss on long lived assets and disposal of property, plant and equipment

     1,339        3,734  

Gain on exit of lease

     (789      —    
  

 

 

    

 

 

 

Total items not affecting cash

     24,102        343,929  
  

 

 

    

 

 

 

Changes in non-cash operating working capital items

     

Trade receivables

     347        2,873  

Commodity taxes recoverable and other receivables

     5,648        (1,479

Prepaid expenses

     (1,851      5,170  

Inventory

     (36,768      (87,243

Biological assets

     33,965        22,168  

Accounts payable and accrued liabilities

     6,269        (1,866

Excise taxes payable

     (2,806      727  
  

 

 

    

 

 

 

Total non-cash operating working capital

     4,804        (59,650
  

 

 

    

 

 

 

Additional supplementary cash flow information is as follows:

 

For the

   nine months ended
April 30, 2021
     year ended
July 31, 2020
 
     $      $  

Property, plant and equipment in accounts payable

     4,150        19,751  

Right-of-use asset additions

     —          24,405  

Capitalized borrowing costs

     1,269        2,385  

Interest paid

     2,409        2,527  
  

 

 

    

 

 

 

32. Comparative Information

The Company has reclassified Impairment loss on inventory within Cost of goods sold, to conform with the current presentation. The amount is disclosed in Note 6. The Company has reclassified purchased extracts inventory from extracts to conform with the current presentation, the amount is disclosed in Note 6.

33. Income Taxes

The Company’s effective income tax rate was nil% for the nine months ended April 30, 2021 (April 30, 2020 – 1.57%). The effective tax rate is different than the statutory rate primarily due to the non-recognition of deferred tax assets.

34. Subsequent Events

Acquisition of Zenabis Global Inc.

On February 15, 2021, the Company entered into a definitive arrangement agreement with Zenabis Global Inc.(or “Zenabis”) under which the Company sought to acquire all of Zenabis’ issued and outstanding common shares through an all-share transaction. A special meeting of the Zenabis shareholders took place May 13, 2021 where the transaction was approved by way of special resolution. The acquisition was finalized on June 1, 2021 by way of a plan of arrangement.

On June 1, 2021, all of the Zenabis issued and outstanding common shares were acquired and converted to 17,579,336 HEXO shares at the prescription exchange ratio of 0.01772 entitling each former Zenabis shareholder 0.01772 of a HEXO common share in exchange for each Zenabis common share held. The estimated value of the acquired shares is $151,358.

The transaction is expected to be treated as business acquisition under IFRS 3, accounted for using the acquisition method.

At-the-Market Offering up to $150 Million

On May 11, 2021 Company established an at-the-market equity program (the “ATM Program”) that allows the Company to issue and sell up to $150,000 (or its U.S. dollar equivalent) of common shares in the capital of the Company (the “Common Shares”) from treasury to the public, from time to time, at the Company’s discretion.

The Company expects to use the net proceeds from the ATM Program for general corporate purposes, which may include: (i) costs associated with the Company’s U.S. expansion plans including the contemplated acquisition of a facility in the State of Colorado and its subsequent retrofitting and improvement; (ii) capital expenditures, including potential capital expenditures to make additional improvements to the production lines at the Company’s Belleville, Ontario facility; (iii) potential future acquisitions; (iv) working capital, including replenishing existing cash resources and working capital which will be used to fund certain transaction and integration costs

 

22


and minimum debt repayments related to the Company’s proposed acquisition of Zenabis; and (v) repayment of additional debts owed by Zenabis.

The Company has raised approximately $16,897 and USD$24,852 through the issuance of 2,298,901 and 4,075,025 common shares, respectively.

Definitive Arrangement to Acquire 48North Cannabis Corp. (“48North”)

On May 17 the Company entered into a definitive arrangement agreement (the “48North Arrangement Agreement”), subject to 48North’s shareholder approval, under which the Company intends to acquire, by way of a court-approved plan of arrangement under the Business Corporations Act (British Columbia), all of 48North’s issued and outstanding common shares in an all-share transaction valued at approximately $50,000 as at May 17, 2021 (the “ 48North Transaction”). Under the terms of the 48North Arrangement Agreement, 48North’s shareholders are expected to receive 0.02366 of a HEXO common share in exchange for each 48North common share held (the “48North Exchange Ratio”).

The 48North Transaction was unanimously approved by the board of directors of each of the Company and 48North (in the case of 48Norths board of directors, after receiving the unanimous recommendation of a special committee formed for purposes of the 48North Transaction). The 48North Transaction will require approval by at least 66 2/3% of the votes cast by the shareholders of 48North present at a special meeting of 48Norths shareholders at a pending future date.

The 48North Transaction also contemplates HEXO providing 48North with a $5,000 subordinated secured bridge loan with a 6-month term within 30 days following signing of the Arrangement Agreement to fund 48North’s short term working capital requirements.

The 48North Arrangement Agreement includes customary provisions, including non-solicitation provisions, subject to the right of 48North to accept a superior proposal in certain circumstances, with HEXO having a period of five business days to exercise a right to match any such superior proposal for 48North. The 48North Arrangement Agreement also provides for a termination fee of $2,000 payable by 48North to HEXO if the 48North Transaction is terminated in certain specified circumstances, as well as reciprocal expense reimbursement provisions if the 48North Transaction is terminated by either party in certain other specified circumstances.

The 48North Transaction is expected to be treated as business acquisition under IFRS 3, accounted for using the acquisition method.

Offering of USD$360m Senior Secured Convertible Notes

On May 27, 2021, the Company closed an offering of USD$360 million aggregate principal amount of senior secured convertible notes (the “Notes”) directly to an institutional purchaser and certain of its affiliates or related funds (collectively, the “Purchaser”).

The Notes were sold at a purchase price of USD $327.6 million or approximately 91.0% of their principal amount. The Notes mature on May 1, 2023. Subject to certain limitations, the Notes will be convertible into freely tradeable common shares of the Company at the option of the Purchaser and, subject to conditions and limitations, at the option of the Company. If not previously converted, all principal repayments of the Notes will be made at a price equal to 110% of the principal amount of the Notes being repaid. The Notes do not bear interest except upon the occurrence of an event of default. The Notes will be issued in registered form, without coupons, under a trust indenture dated May 27, 2021.

Upon closing of the offering, 70% of the net proceeds have been placed into escrow with a third party. The escrowed funds may be released upon the satisfaction of certain conditions related to the proposed Redecan Definitive Arrangement (below). If the release conditions are satisfied prior to December 1, 2021 the escrowed funds and the interest earned thereon will be released to HEXO and will be used for purposes of completing the Redecan acquisition.

The Company expects to use substantially all of the net proceeds from the Offering to fund the acquisition of Redecan.

Definitive Arrangement to Acquire Redecan

On May 28, 2021 the Company entered into a definitive share purchase agreement (the “Share Purchase Agreement”) to acquire all of the outstanding shares of the entities that carry on the business of Redecan, Canada’s largest privately-owned licensed producer, for a purchase price of $925 million payable in a combination of cash and through the issuance of common shares of HEXO and subject to certain customary adjustments (the “Redecan Transaction”).

Under the terms of the Share Purchase Agreement, the $925 million purchase price will be paid to the Redecan shareholders as $400 million of consideration due on closing paid in cash and $525 million of consideration due on closing paid through the issuance of HEXO common shares at an implied price per share of $7.53.

Under TSX rules, the Redecan Transaction requires a simple majority approval of HEXO’s shareholders. HEXO expects to convene a meeting of shareholders to be held in August 2021 for the purpose of submitting the Redecan Transaction to shareholders for approval. The Redecan Transaction has been unanimously approved by HEXO’s board of directors.

The Redecan Transaction is expected to be treated as business acquisition under IFRS 3, accounted for using the acquisition method.

 

23